focus -WSS

focus

author：knowledge 2025-09-06 03:26:06 - browse：7139

Editor’s note: A recording of the event is embedded below.

Several biosimilar versions of Humira, which for years has been the world’s best-selling medicine, entered the U.S. market over the past year. What has that meant for insurance coverage and the way drugmakers are marketing these medicines? Join leading experts to discuss the impact on the industry and patients.

Sponsor introduction

Thomas Newcomer, vice president and head of U.S. market access, Samsung Bioepis (sponsor)

Featured speakers

Chris M. Brown, president, McAteer
Michael Gonzales, independent health care consultant, Michael Gonzales, LLC; former national and regional account director, AbbVie
Fran Gregory, MBA, PharmD, vice president of emerging therapies, Cardinal Health
Ed Silverman, Pharmalot columnist, senior writer, STAT (moderator)

WSS

Wildfire pollution widens asthma inequities on Long Island

5 important ways Henrietta Lacks changed medical science

Sage hopes for a blockbuster in antidepressant now before FDA

Long Covid research funding gets a major boost from NIH

Wildfire pollution widens asthma inequities on Long Island

What to expect as Trump is arraigned on his Jan 6. indictment

hotspot

focus

Sponsor introduction

Featured speakers

Sponsored By

focus

Drug repurposing or repositioning? The language matters

What to expect as Trump is arraigned on his Jan 6. indictment

Virginia high school admissions case could be legal follow

EQRx, failed developer of low

The high cost of giving birth even with insurance

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Hollywood unions extend contract negotiations for actors

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Peter Hotez and the public health issue of online harassment

AMAs digital advisors table RPM coding reform proposal, again

knowledge

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

AMAs digital advisors table RPM coding reform proposal, again

Here’s what’s in the FDA plan to include pregnant women in clinical trials

New safety details link Apellis eye drug to rare cases of blindness

What to expect as Trump is arraigned on his Jan 6. indictment

EQRx, failed developer of low

hotspot

hotspot

entertainment

entertainment